Instrument Inactif

Communiqués Delcath Systems, Inc. Nasdaq

Actions

US24661P1049

Equipement, fournitures et distribution médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

09/07	Delcath Systems annonce le traitement d'un premier patient dans l'essai clinique de phase 2 de HEPZATO contre le cancer du sein métastatique à prédominance hépatique	CI
09/07	Delcath Systems administre la première dose dans le cadre d'un essai de phase intermédiaire pour Hepzato	MT

Communiqués

16/07	Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/07	Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Breast Cancer	AQ
09/07	Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer	BU
26/05	Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts	BU
15/05	Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
12/05	Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference	BU
07/05	Delcath Systems Reports First Quarter 2026 Results and Business Highlights	BU
07/05	Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026	BU
23/04	Delcath Systems to Host First Quarter 2026 Earnings Call	BU
06/04	Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma	BU
01/04	Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting	BU
03/03	Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology	BU
26/02	Delcath Systems Reports Fourth Quarter and Full Year 2025 Results	BU
12/02	Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call	BU
27/01	Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference	BU
21/01	Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
09/01	Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results	BU
31/12	Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma	BU
03/12	Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma	BU
20/11	Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program	BU
18/11	Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma	BU
14/11	Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
13/11	Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients	BU
06/11	Delcath Systems to Participate in Upcoming Investor Conferences	BU
04/11	Delcath Systems Reports Third Quarter 2025 Results and Business Highlights	BU